Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...